CASI - CASI Pharmaceuticals, Inc Projected Sales Volume

CASI Pharmaceuticals results are independent of market cycles, relying solely on the success of oncology drugs in China. Exclusive distribution rights for Evomela ensure a stable niche capture. The company's sales guidance visualizes this trend, where the current value is 0.00. The development of new drugs is accelerating through robotic screening, which eliminates human error in laboratories.

CASI - casipharmaceuticals.com Projected Sales Volume over the range 07/04/2022 - 03/14/2026

Analytical breakdowns and data insights for company CASI Pharmaceuticals, Inc (CASI)

- stock quotes and analyst forecast:

Stock Price CASI Pharmaceuticals|CASI - Broker Consensus Forecast

- market capitalization statistics:

Market Capitalization CASI Pharmaceuticals Inc.|CASI - Real Price to Acquire Entire Company

- book capitalization information:

Book Value per Share CASI Pharmaceuticals|CASI - Book Capitalization|Market Value to Book Value Ratio casipharmaceuticals.com|CASI - Company Total Asset Base

- issuer credit burden and liquidity indicators:

Total Debt to Capital CASI Pharmaceuticals|CASI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio CASI Pharmaceuticals|CASI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio CASI Pharmaceuticals Inc.|CASI - Long-Term Liabilities|Company Short-Term Debts CASI Pharmaceuticals|Quick Ratio casipharmaceuticals.com

- earnings and market ratios statistics:

CASI - Net Profit|Expected Profit CASI Pharmaceuticals|CASI - Company Value to Net Income|Future Price to Earnings CASI Pharmaceuticals|CASI - Price/Earnings to Growth Multiple|EV/EBITDA Multiple CASI Pharmaceuticals Inc.|CASI - Operating profit EBITDA|Net earnings per share (EPS TTM) CASI Pharmaceuticals|CASI - Net earnings per share for the last 12 months|Quarterly EPS earnings growth casipharmaceuticals.com|CASI - Earnings per share growth rate in current year|Expected earnings per share growth for next year CASI Pharmaceuticals

- sales volume and revenue indicators:

CASI - Revenue and Sales Volume|Company Future Sales Volume CASI Pharmaceuticals|CASI - Market Cap to Sales Volume|Forward P/S Multiple CASI Pharmaceuticals Inc.

Fundamental valuation:CASI CASI Pharmaceuticals, Inc.

Fundamental asset selection requires an analysis of long-term revenue sustainability. This indicator measures a business's ability to generate stable cash flow, filtering out random spikes. For CASI Pharmaceuticals, this confirms the effectiveness of its Western drug licensing model, which minimizes R&D risks. The stability of the organization's projected sales indicates a predictable expansion of its market share in China. The trend in the organization's projected sales allows for a distinction between organic growth and temporary market conditions.

Competitor analysis for CASI Pharmaceuticals

Projected Sales Volume TGTX|arcellx.com - Company Revenue Forecast|Projected Sales Volume IRON (Disc Medicine)|SNDX - Company Future Sales Volume|Kura Oncology Corp - Projected Sales Volume|ADCT - Projected Sales Volume|foghorntx.com (FHTX) - Company Projected Revenue|VOR - Company Future Sales|NKTX (Nkarta Inc.) - Projected Sales Volume|Coeptis (COEP) - Company Future Sales|Company Future Sales Volume ATNM (Actinium Pharmaceuticals Inc)|ESLA (Estrella Immunopharma Corp) - Company Future Revenue|Company Projected Revenue Marker Therapeutics, Inc. MRKR|INAB (in8bio.com) - Company Expected Revenue|Eterna Therapeutics Inc - Projected Sales Volume|Company Future Revenue GTBP (GT Biopharma Inc)|APTO: Projected Sales Volume|Bio-Path Holdings, Inc (BPTH) - Projected Sales Volume|Company Projected Revenue MEI Pharma, Inc.|VINC: Company Future Revenue